Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-avibactam versus doripenem for complicated urinary tract infection
2011-005722-21Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2012
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in complicated urinary tract infection (cUTI) and acute pyelonephritis comparing Ceftazidime-avibactam arm with Doripenem arm (2 arms). Primary endpoints: Symptomatic resolution of UTI-specific symptoms at Day 5 and Microbiological response in the mMITT set. Started Apr 2012; status: completed.
02
Drugs
ceftazidime + avibactamdoripenem
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on 2011-005722-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005722-21.